| アブストラクト | BACKGROUND: With the widespread use of immune checkpoint inhibitors (ICI), rare cutaneous immune-related adverse events (cirAEs), including ICI-induced eosinophilic fasciitis (ICI-EF), are increasingly encountered. However, data on its clinical presentation and optimal therapeutic approaches remain sparse. OBJECTIVES: This study aimed to further characterize the clinical features and outcomes of ICI-EF. METHODS: This retrospective observational study analysed clinical features, treatment strategies and outcomes of ICI-EF cases from EADV Task Force-affiliated dermatology departments, complemented by cases from the current available literature and two international pharmacovigilance databases. Patient demographics, clinical characteristics, diagnostics, treatment and follow-up data were extracted from the medical records and databases. RESULTS: We present 121 ICI-EF cases from the EADV Task Force (n = 15), FPVD (n = 21), VigiBase(R) (n = 45) and the literature (n = 40). The most prevalent underlying malignancy in all groups was melanoma (50%), with PD-1 inhibitor monotherapy (81%) being the predominant offending drug class. The median time to ICI-EF onset was 10 months (IQR 6.8-16.3; range < 1-36). Detailed clinical information was available for 76 of the 121 cases (63%), revealing a highly variable clinical presentation. Treatment primarily involved ICI discontinuation (83%) and systemic corticosteroids (80%), followed by methotrexate (41%), intravenous immunoglobulins (12%) and mycophenolate mofetil (13%), resulting in the partial or complete resolution of ICI-EF symptoms (66%). CONCLUSIONS: ICI-EF is a rare heterogeneous cirAE with varying clinical features and significant morbidity. Early recognition and timely treatment are key to ensuring ICI continuation and preserve oncologic outcomes. |
|---|
| 投稿者 | Bruijn, Tristan V M; Gerard, Alexandre O; Labat, Maelys; Apalla, Zoe; Binsbergen, Wouter van; Koumaki, Dimitra; Rivet, Valerian; Dezoteux, Frederic; Giacchero, Damien; Ardern-Jones, Michael R; Heelan, Kara; Hirner, Jesse P; Mayor, Ander; Labots, Mariette; Starink, Markus V; Laken, Conny J van der; Sibaud, Vincent; Elshot, Yannick S |
|---|
| 組織名 | Department of Dermatology, Amsterdam UMC, Amsterdam, The Netherlands.;Department of Dermatology, The Netherlands Cancer Institute-Antoni Van;Leeuwenhoek, Amsterdam, The Netherlands.;Department of Clinical Pharmacology, Universite Cote d'Azur, University Hospital;Centre of Nice, Nice, France.;Laboratory of Molecular Physio Medicine (LP2M), UMR 7370, CNRS, Universite Cote;d'Azur, Nice, France.;Saint Louis Regional Pharmacovigilance Centre, Clinical Investigation Centre;(INSERM CIC 1427), Saint-Louis Hospital, Paris, France.;Second Dermatology Department, School of Medicine, Faculty of Health Sciences,;Aristotle University of Thessaloniki, Thessaloniki, Greece.;Department of Rheumatology & Clinical Immunology, Amsterdam UMC, Amsterdam, The;Netherlands.;Dermatology Department, University Hospital of Heraklion, Crete, Greece.;Internal Medicine and Immunopathology Department, The Cancer University of;Toulouse Oncopole, Toulouse University Hospital, Toulouse, France.;Service de Dermatologie, Hopital Claude-Huriez, Universite de Lille, INFINITE;Institute for Translational Research in Inflammation, Lille, France.;Oncology Departement, Centre Antoine Lacassagne, Nice, France.;Clinical Experimental Sciences, Faculty of Medicine, University of Southampton,;Southampton, UK.;Department of Dermatology, University Hospitals Southampton NHS Foundation Trust,;The Royal Marsden Foundation Trust, London, UK.;Department of Dermatology, University of Nebraska, Omaha, Nebraska, USA.;Servicio de Dermatologia, Hospital Universitario La Paz, Madrid, Spain.;Department of Medical Oncology, Amsterdam UMC, Cancer Center Amsterdam,;Amsterdam, The Netherlands.;Department of Oncodermatology, Oncopole Claudius Regaud, Institut Universitaire;du Cancer, Toulouse Oncopole, Toulouse, France. |
|---|
